Odanacatib

• CAT Number: I004270
• CAS Number: 603139-19-1
• Molecular Formula: C25H27F4N3O3S
• Molecular Weight: 525.61
• Purity: ≥95%
• Synonyms: (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide
• Target: Cathepsin
• Solubility: DMSO ≥102mg/mL Water <1.2mg/mL Ethanol ≥2.9mg/mL
• Storage: 3 years -20C powder
• IC50: 0.2 nM/1 nM(human/rabbi cathepsin K)
• InChI: InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1
• InChIKey: FWIVDMJALNEADT-SFTDATJTSA-N
• SMILES: CS(C(C=C1)=CC=C1C2=CC=C([C@@H](C(F)(F)F)N([H])[C@H](C(N([H])C3(CC3)C#N)=O)CC(F)(C)C)C=C2)(=O)=O

Odanacatib(CAT: I004270) is a selective inhibitor of cathepsin K, a cysteine protease highly expressed in osteoclasts and critical for bone resorption. By targeting cathepsin K, Odanacatib reduces the degradation of collagen and other bone matrix proteins, making it a promising therapeutic candidate for osteoporosis and other bone-related metabolic disorders. This compound has been extensively studied in preclinical and clinical research for its potential to improve bone density while minimizing effects on bone formation. Odanacatib is a valuable tool in exploring the regulation of bone remodeling and the development of targeted therapies for skeletal diseases.